Schizophrenia Research

Schizophrenia is a chronic, debilitating mental disorder affecting 1-2% of the global population. Symptoms are split into two types; 'positive' symptoms, including delusions and hallucinations, and 'negative' symptoms, including anhedonia and lack of motivation. Studies suggest that genetics, early environment, neurobiology, psychological and social processes are important contributory factors; some recreational and prescription drugs appear to cause or worsen symptoms. Several neurobiological alterations in brain structure, physiology and neurochemistry have been documented, along with an ever-increasing list of susceptibility genes.

Schizophrenia Research Products Targets

Products for Schizophrenia Research - Page 54

  1. Cat.No. Product Name Information/Activity
  2. BCC7753 DL-AP5 Sodium salt 1303993-72-7 DL-AP5 Sodium salt chemical structure
  3. BCC6553 D-AP5 D-AP5 is a NMDA receptor antagonist. D-AP5 chemical structure
  4. BCC6552 DL-AP5 76326-31-3 DL-AP5 chemical structure
  5. BCC6554 L-AP5 79055-67-7 L-AP5 chemical structure
  6. BCC6551 DL-AP7 78966-69-5 DL-AP7 chemical structure
  7. BCC6631 Arcaine sulfate 14923-17-2 Arcaine sulfate chemical structure
  8. BCC6602 (R)-4-Carboxyphenylglycine 134052-68-9 (R)-4-Carboxyphenylglycine chemical structure
  9. BCC7078 CGP 37849 CGP 37849 is a potent, competitive and orally active N-methyl-D-aspartate (NMDA) receptor antagonist. CGP 37849 is an anticonvulsant in rodents and has antidepressant and anxiolytic-like effects. CGP 37849 chemical structure
  10. BCC7053 CGP 39551 127910-32-1 CGP 39551 chemical structure
  11. BCC7087 CGP 78608 hydrochloride CGP 78608 hydrochloride is a highly potent and selective antagonist at the glycine-binding site of the NMDA receptor, with an IC50 of 6 nM. CGP 78608 acts as a potentiator of GluN1/GluN3A-mediated glycine currents, with an estimated EC50 in the low nM range (26.3 nM). Anticonvulsant activity. CGP 78608 hydrochloride chemical structure

Items 531 to 540 of 709 total